Table 2.
Univariate analysis of the impact of clinical variables on overall survival
| HR (95% CI) | P-value | |
|---|---|---|
| Age | 1.0 (0.99, 1.02) | 0.823 |
| ECOG | ||
| 0 | 1.00 | 0.255 |
| 1 + 2 + 3 | 1.33 (0.82, 2.16) | |
| Elevated LDH | ||
| N | 1.00 | 0.017 |
| Y | 1.96 (1.13, 3.4) | |
| Liver involvement | ||
| N | 1.00 | 0.173 |
| Y | 1.43 (0.85, 2.4) | |
| Checkpoint inhibitor | ||
| PD1 + CTLA-4 | 1.00 | 0.232 |
| CTLA-4 | 1.02 (0.5, 2.07) | |
| PD1 | 0.49 (0.17, 1.37) | |
| Concurrent radiation | ||
| WBRT | 1.00 | 0.23 |
| SRS | 0.72 (0.42, 1.23) | |
| Prior systemic therapy | ||
| Chemotherapy | 1.00 | 0.943 |
| BRAF ± MEK inhibitor | 1.03 (0.44, 2.32) | |
| Prior BRAF inhibitor | ||
| No | 1.00 | 0.17 |
| Yes | 1.63 (0.81, 3.29) | |
| Driver mutational status | ||
| BRAF V600E | 0.73 (0.38, 1.42) | 0.36 |